The safety of blood components and derivatives.
An overview of the steps taken to ensure the safety of blood components and derivatives is provided. A brief discussion of hereditary bleeding disorders (hemophilia A, B, and von Willebrand's disease) is included, and the safety of derivatives available for their treatment is discussed, as well as the method of production and the level of safety of derivatives such as factor VIII and factor IX concentrates.
Julius
C
C
Department of Pathology, University of Vermont College of Medicine, Burlington.
Westphal
R G
RG
D001771:Blood Banks / Q000592:standards; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D001782:Blood Donors; D001793:Blood Preservation; D001803:Blood Transfusion / Q000592:standards; D003219:Confidentiality; D015925:Cryopreservation; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D015491:HTLV-II Infections / Q000517:prevention & control / Q000635:transmission; D006467:Hemophilia A / Q000628:therapy; D006509:Hepatitis B / Q000517:prevention & control* / Q000635:transmission; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006526:Hepatitis C / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D012449:Safety; D013587:Syphilis / Q000517:prevention & control* / Q000635:transmission; D065227:Transfusion Reaction; D014838:Volunteers; D014842:von Willebrand Diseases / Q000628:therapy
D001779:Blood Coagulation Factors; D006514:Hepatitis B Surface Antigens